> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Jardiance sNDA
- URL: https://www.fdaweb.com/panel-to-review-jardiance-snda/
- Published: 2019-10-04T12:00:00.000Z
- Updated: 2026-09-15T01:54:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145166

*Federal Register* notice: FDA announces an 11/13 Endocrinologic and Metabolic Drugs Advisory Committee meeting. Panel members are scheduled to discuss a Boehringer Ingelheim Pharmaceuticals supplemental NDA for Jardiance (empagliflozin) oral tablets, seeking an indication as an adjunct to insulin therapy to improve glycemic control in adults with Type 1 diabetes mellitus. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-21834.pdf?ref=fdaweb.com).